Revance Therapeutics (RVNC)

$3.65 +0.01 (0.27%)
Market Cap 381.02M
Revenue (ttm) 234.04M
Net Income (ttm) -323.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -138.43%
Debt to Equity Ratio -0.13
Volume 4,123,100
Avg Vol 3,110,214
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 47%
Beta 0.90
Analysts Sell
Price Target $8.00

Latest News on RVNC

RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Feb 18, 2025, 8:31 PM EST - 4 days ago

RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Feb 13, 2025, 5:45 AM EST - 9 days ago

Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights – RVNC

Feb 12, 2025, 12:48 PM EST - 10 days ago

Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights – RVNC

Crown Laboratories Completes Acquisition of Revance Therapeutics

Feb 7, 2025, 3:46 PM EST - 15 days ago

Crown Laboratories Completes Acquisition of Revance Therapeutics

Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics

Feb 6, 2025, 8:39 AM EST - 16 days ago

Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics

Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer

Feb 5, 2025, 8:00 AM EST - 17 days ago

Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer

Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline

Jan 31, 2025, 7:30 AM EST - 22 days ago

Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline

Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Jan 23, 2025, 5:45 AM EST - 4 weeks ago

Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer

Jan 21, 2025, 8:00 AM EST - 4 weeks ago

Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer

Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

Jan 13, 2025, 8:30 AM EST - 5 weeks ago

Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

Jan 9, 2025, 5:45 AM EST - 6 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC

Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Jan 8, 2025, 12:00 PM EST - 6 weeks ago

Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith

Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash

Jan 6, 2025, 9:00 AM EST - 6 weeks ago

Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash

REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC

Dec 17, 2024, 2:31 PM EST - 2 months ago

REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNC

Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share

Dec 12, 2024, 8:00 AM EST - 2 months ago

Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share

Revance agrees to lower-priced buyout offer by Crown Laboratories

Dec 9, 2024, 9:12 AM EST - 2 months ago

Revance agrees to lower-priced buyout offer by Crown Laboratories

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Dec 9, 2024, 8:30 AM EST - 2 months ago

Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement

Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029

Nov 29, 2024, 4:20 AM EST - 3 months ago

Hyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029